Mersana Therapeutics, a company specializing in the development of antibody drug conjugates, has named Anna Protopapas as president and chief executive officer (CEO).
Ms. Protopapas was most recently president of Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Ms. Protopapas and Elaine V. Jones, PhD, executive eirector of Pfizer Venture Investments, have joined Mersana’s board of directors. David Mott, general partner at NEA, who assumed the role of executive chairman in January 2014, remains chairman.
Ms. Protopapas served as a member of the Executive Committee of Takeda and held various senior management positions, including as president of Millennium, where she was responsible for leading Takeda’s oncology business, as well as executive vice president of global business development, where she was responsible for all global acquisitions, partnering, licensing, and venture investing. In this role, Ms. Protopapas was instrumental in developing and executing a business plan that helped globalize Takeda, including leading the company’s $12 billion acquisition of Nycomed. Prior to serving on Takeda’s Executive Committee, Ms. Protopapas served on Millennium’s Executive Committee as senior vice president of strategy and business development, where she led the company’s business development initiatives, played an integral role in the transformation of the company from a genomics start-up to a fully integrated oncology leader, and led the process that resulted in the $8.8 billion sale of Millennium to Takeda.
Source: Mersana Therapeutics